

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Prescient Therapeutics Limited
<b>ABN</b>	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Steven Lee Yatomi-Clarke
<b>Date of last notice</b>	6 May 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> <li>1. Arrow Wealth Ltd &lt;Berbay Family A/C&gt; (a controlled entity of Mr Yatomi-Clarke)</li> <li>2. Novetera Pty Ltd &lt;SAYC Super Fund A/C&gt; (a controlled entity of Mr Yatomi-Clarke)</li> <li>3. Alexandra Elizabeth Yatomi-Clarke</li> </ol>
<b>Date of change</b>	24 August 2020
<b>No. of securities held prior to change</b>	<p><b>Direct</b></p> <p>2,000,000 Unlisted Options exercisable at \$0.1021 (10.21 cents) per option, expiring 18 December 2022</p> <p>3,500,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023</p> <p><b>Indirect</b></p> <ol style="list-style-type: none"> <li>1. 3,245,000 Fully paid ordinary shares</li> <li>2. 1,172,295 Fully paid ordinary shares 97,692 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023</li> <li>3. 172,500 Fully paid ordinary shares</li> </ol>

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

Class	Fully Paid Ordinary Shares
Number acquired	545,455 Fully Paid Ordinary Shares
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$30,000.00
No. of securities held after change	<p><b>Direct</b></p> <p>2,000,000 Unlisted Options exercisable at \$0.1021 (10.21 cents) per option, expiring 18 December 2022</p> <p>3,500,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023</p> <p><b>Indirect</b></p> <p>1. 3,245,000 Fully paid ordinary shares</p> <p>2. 1,717,750 Fully paid ordinary shares 97,692 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023</p> <p>3. 172,500 Fully paid ordinary shares</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities following participation in Share Purchase Plan as announced on 27 July 2020

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

+ See chapter 19 for defined terms.